Navigation Links
NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Date:8/8/2011

litary and in the general population," said Dr. Russell Taichman, Professor of Dentistry, Department of Periodontics and Oral Medicine at the University of Michigan's School of Dentistry who will work with the Company on the study.  

Dr. Taichman added, "Osteoporosis is a major medical condition affecting 75 million people worldwide and causing significant morbidity and mortality in the aging population and the increased incidence of fractures is the major cause of death from osteoporosis. In 2005, the estimated cost burden of fractures due to osteoporosis was $19 billion and that is expected to rise to over $25 billion by the year 2025. In addition to being a major concern for the general healthcare community, osteoporosis and related bone fractures have become a concern for the military with significant loss of duty time across all branches of the military due to related stress fractures."

Dr. Denis Rodgerson, NeoStem's Director of Stem Cell Science and Principal Investigator for the study commented, "We are honored to receive this award as it enables us, together with Dr. Taichman as co-Principal Investigator and his colleague Dr. Laurie K. McCauley, Chair, Department of Periodontics and Oral Medicine at the University of Michigan's School of Dentistry and Professor of Pathology at  the University of Michigan Medical School, to explore the significant therapeutic regenerative potential for VSEL™ Technology in autologous, cell-based therapies for the treatment of osteoporosis and other diseases of the bone."

NeoStem has a worldwide exclusive license to VSEL™ Technology which uses very small stem cells found in adult bone marrow that have several physical characteristics that are generally found in embryonic stem cells.  NeoStem has shown that these cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what NeoStem believes to be a population of stem cells that the potent
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
2. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
3. NeoStem to Present at Two Investor Events This Month
4. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
5. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
6. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
7. NeoStem Acquires Progenitor Cell Therapy
8. NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards
9. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
10. FOX Business Network Airing In-Depth Look at NeoStem
11. NeoStem to Present at Rodman & Renshaws 12th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... Inc., its wholly owned subsidiary, announced today they have ... Army Medical Research and Materiel Command (USAMRMC) for consideration ... stem cells (ASCs) harvested from liposuction for treating Traumatic ...
... PARSIPPANY, N.J., May 4 Arno Therapeutics, Inc. (OTC ... oncology therapeutics, today announced that it has voluntarily filed ... ("SEC") in order to deregister its common stock under ... a result, effective immediately, Arno,s obligation to file periodic ...
... Develop Powerful Tools for Detecting Ovarian Cancer Earlier FRANKLIN ... (Becton, Dickinson and Company) (NYSE: BDX ) ... a worldwide development and supply agreement for oncology diagnostic ... develop diagnostic products that incorporate Fujirebio Diagnostics, cancer biomarkers ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... infects more than 170 million people worldwide. Approximately 80 ... cirrhosis, cancer and also hepatic iron overload. A new ... School of Medicine reveals that HCV not only alters ... 1 (TfR1) but that TfR1 also mediates HCV entry. ...
... For more than a decade, scientists have suspected that hairpin-shaped ... scientists at NC State University have found the first example ... The research, published online in Proceedings of the ... describes how one strand of micro-RNA reduced by more than ...
... and the Woodrow Wilson International Center for Scholars are ... Foundation (NSF) to help realize potential benefits and to ... The grant is supported jointly by three units ... the Division of Environmental Biology, and the Engineering Directorate. ...
Cached Biology News:New Loyola study on hepatitis C virus entry factor 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
Biology Products: